论文部分内容阅读
目的:观察缬沙坦联合培哚普利对慢性心力衰竭(CHF)的治疗效果,以及对患者心功能、血浆脑利钠肽(BNP)、C反应蛋白(CRP)和IL-6的影响。方法:95例CHF患者随机分为缬沙坦治疗组(30例)、培哚普利治疗组(30例)和联合治疗组(35例),患者均予以常规西医治疗,缬沙坦治疗组或培哚普利治疗组在常规治疗基础上加用缬沙坦或培哚普利,联合治疗组则同时加用缬沙坦和培哚普利。观察治疗效果及患者心功能变化,检测治疗前后血浆BNP、CRP、IL-6的浓度。结果:联合治疗组总有效率达到91.43%,高于缬沙坦治疗组73.33%和培哚普利53.33%的总有效率(P<0.05);与缬沙坦治疗组和培哚普利治疗组相比,缬沙坦联合培哚普利可有效改善患者心功能指标,降低血浆BNP、CRP、IL-6含量。结论:缬沙坦联合培哚普利能有效改善心功能,调节细胞因子表达,优于单用缬沙坦或培哚普利治疗。
Objective: To observe the effect of valsartan combined with perindopril on the treatment of chronic heart failure (CHF) and its effect on cardiac function, plasma brain natriuretic peptide (BNP), C-reactive protein (CRP) and IL-6. Methods: Ninety-five CHF patients were randomly divided into valsartan treatment group (30 cases), perindopril treatment group (30 cases) and combination therapy group (35 cases). All patients were treated with routine western medicine and valsartan treatment group Or perindopril treatment group on the basis of conventional treatment with valsartan or perindopril, combination therapy group also added valsartan and perindopril. The therapeutic effects and changes of cardiac function were observed. The concentrations of plasma BNP, CRP and IL-6 were measured before and after treatment. Results: The total effective rate was 91.43% in the combined treatment group, which was higher than the total effective rate of 73.33% and 53.33% of the valsartan group (P <0.05). Compared with the valsartan treatment group and the perindopril treatment group Compared with the control group, valsartan combined with perindopril could effectively improve the cardiac function and reduce the plasma levels of BNP, CRP and IL-6. Conclusion: Valsartan combined with perindopril can effectively improve cardiac function and regulate the expression of cytokines, which is better than valsartan or perindopril alone.